(S (PP (IN In) (NP (NP (NN line)) (PP (IN with) (NP (NP (JJ recent) (NNS advances)) (PP (IN in) (NP (NP (JJ neural) (NN drug) (NN design)) (CC and) (NP (NN sensitivity) (NN prediction)))))))) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ novel) (NN architecture)) (PP (IN for) (NP (NP (JJ interpretable) (NN prediction)) (PP (IN of) (NP (NN anticancer) (NN compound) (NN sensitivity))) (VP (VBG using) (NP (DT a) (JJ multimodal) (JJ attention-based) (JJ convolutional) (NN encoder))))))) (. .))
(S (NP (PRP$ Our) (NN model)) (VP (VBZ is) (VP (VBN based) (PP (IN on) (NP (NP (NP (DT the) (CD three) (JJ key) (NNS pillars)) (PP (IN of) (NP (NN drug) (NN sensitivity)))) (: :) (NP (NP (NP (NP (NNS compounds) (POS â€º)) (NN structure)) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (DT a) (NNP SMILES) (NN sequence)))))) (, ,) (NP (NP (NN gene) (NN expression) (NNS profiles)) (PP (IN of) (NP (NNS tumors)))) (CC and) (NP (NP (JJ prior) (NN knowledge)) (PP (IN on) (NP (JJ intracellular) (NNS interactions))) (PP (IN from) (NP (JJ protein-protein) (NN interaction) (NNS networks))))))))) (. .))
(S (NP (PRP We)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (PRN (SINV (PRP$ our) (JJ multiscale) (JJ convolutional) (JJ attention-based) (PRN (-LRB- -LRB-) (NNP MCA) (-RRB- -RRB-)))) (VBP encoder)) (VP (ADVP (RB significantly)) (VBZ outperforms) (NP (NP (DT a) (NN baseline) (NN model)) (VP (VBN trained) (PP (IN on) (NP (NP (NNP Morgan) (NNS fingerprints)) (, ,) (NP (NP (DT a) (NN selection)) (PP (IN of) (NP (NNS encoders))) (VP (VBN based) (PP (IN on) (NP (NNP SMILES))))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (ADJP (RB previously) (VBN reported)) (NN state)) (PP (IN of) (NP (DT the) (NN art))) (PP (IN for) (NP (JJ multimodal) (NN drug) (NN sensitivity) (NN prediction)))) (PRN (-LRB- -LRB-) (S (S (NP (NNP R2)) (VP (NNP =) (NP (CD 0.86)))) (CC and) (S (NP (NNP RMSE)) (VP (NNP =) (NP (CD 0.89))))) (-RRB- -RRB-))))))))))) (. .))
(S (ADVP (RB Moreover)) (, ,) (NP (NP (DT the) (NN explainability)) (PP (IN of) (NP (PRP$ our) (NN approach)))) (VP (VBZ is) (VP (VBN demonstrated) (PP (IN by) (NP (NP (DT a) (JJ thorough) (NN analysis)) (PP (IN of) (NP (DT the) (NN attention) (NNS weights))))))) (. .))
(S (NP (PRP We)) (VP (VBP show) (SBAR (SBAR (IN that) (S (NP (DT the) (JJ attended) (NNS genes)) (VP (ADVP (RB significantly)) (VBP enrich) (NP (JJ apoptotic) (NNS processes))))) (CC and) (SBAR (IN that) (S (NP (DT the) (NN drug) (NN attention)) (VP (VBZ is) (VP (ADVP (RB strongly)) (VBN correlated) (PP (IN with) (NP (DT a) (JJ standard) (NN chemical) (NN structure) (NN similarity) (NN index))))))))) (. .))
(S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (DT a) (NN case) (NN study)) (PP (IN of) (NP (NP (CD two) (NN receptor) (NN tyrosine) (NN kinase) (PRN (-LRB- -LRB-) (NNP RTK) (-RRB- -RRB-)) (NNS inhibitors)) (VP (VBG acting) (PP (IN on) (NP (DT a) (NN leukemia) (NN cell) (NN line))))))) (, ,) (S (VP (VBG showcasing) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (DT the) (NN model))) (S (VP (TO to) (VP (VB focus) (PP (IN on) (NP (NP (JJ informative) (NNS genes)) (CC and) (NP (NP (JJ submolecular) (NNS regions)) (PP (IN of) (NP (DT the) (CD two) (NNS compounds))))))))))))) (. .))
(S (NP (NP (NP (DT The) (JJ demonstrated) (NN generalizability)) (CC and) (NP (DT the) (NN interpretability))) (PP (IN of) (NP (PRP$ our) (NN model)))) (VP (VB testify) (NP (NP (PRP$ its) (JJ potential)) (PP (IN for) (NP (NP (JJ in-silico) (NN prediction)) (PP (IN of) (NP (NP (NN anticancer) (NN compound) (NN efficacy)) (PP (IN on) (NP (JJ unseen) (NN cancer) (NNS cells)))))))) (, ,) (S (VP (VBG positioning) (NP (PRP it)) (PP (IN as) (NP (NP (DT a) (JJ valid) (NN solution)) (PP (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (JJ personalized) (NNS therapies))))) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NP (DT the) (NN evaluation)) (PP (IN of) (NP (NN candidate) (NNS compounds))) (PP (IN in) (NP (JJ de) (JJ novo) (NN drug) (NN design))))))))))) (. .))
